Advertisement

Picture Berlin Partner HealthCapital Bionnale 2018 Germany June 600x60px
Document › Details

Euronext N.V.. (5/30/18). "Press Release: Digital Biotech Voluntis Lists on Euronext". Paris.

Organisations Organisation Euronext Paris S.A.
  Group Euronext (Group)
  Organisation 2 Voluntis S.A.
  Group Voluntis (Group)
Products Product digital health
  Product 2 investment banking
Index term Index term Voluntis–SEVERAL: investment, 201805 IPO €30.1m at Euronext Paris with 2.15m new shares at €14/share
     


Euronext today welcomes Voluntis, a company specialised in digital therapeutics, on its listing on Euronext’s regulated market in Paris.

Voluntis’ primary mission is to empower people suffering from chronic conditions to self-manage their treatments on a daily basis, thereby providing real-world outcomes. To do so, Voluntis develops and markets digital therapeutics, which personalise treatment and support patients in the day-to-day management of their condition. Its therapeutic solutions, which work in real time using digital clinical algorithms, provide patients with tailored recommendations via a mobile app and their care team with patient data via a web app. The latter enables the team to adjust treatment dosage and manage related symptoms to the patients’ needs. Voluntis’ digital therapeutics can enhance real-life treatment efficacy and patient adherence, addressing a major medico-economic challenge.

Voluntis was listed through the admission to trading on 30 May 2018 of the 7,567,661 shares making up its equity, comprising of 2,150,000 new shares issued under a Global Offering[1].

The admission and issue price was set at €14 per share. Market capitalisation was €105.9 million on the day of listing. The offering raised €30.1 million altogether.

“I’m delighted to announce that our initial public offering - a defining moment in Voluntis’ development - has been completed successfully on Euronext Paris. It will pave the way for our expansion, into the United States, where we plan to expand our sales coverage significantly. It will also consolidate our digital therapeutics portfolio, including the continued development of our proprietary multi-cancer solution. The funds we raised will boost our ability to complete the large-scale roll out of next-generation healthcare solutions that personalise treatment and support patients on a daily basis with the management of their illness”, commented Pierre Leurent, Chief Executive Officer and co-founder of Voluntis. “We wish to thank our longstanding shareholders, our partner Sanofi and our new shareholders for their participation in this fundraising.”


[1] The Global Offering was made up of a Public Offering that included an Open Price Public Offering and a Global Placement with institutional investors in France and other countries.


About Euronext

Euronext is the leading pan-European exchange in the Eurozone, covering Belgium, France, Ireland, The Netherlands, Portugal and the UK. With 1,300 listed issuers worth €3.7 trillion in market capitalisation as of end March 2018, Euronext is an unmatched blue chip franchise that has 25 issuers in the Morningstar® Eurozone 50 Index? and a strong diverse domestic and international client base. Euronext operates regulated and transparent equity and derivatives markets and is the largest centre for debt and funds listings in the world. Its total product offering includes Equities, Exchange Traded Funds, Warrants & Certificates, Bonds, Derivatives, Commodities and Indices. Euronext also leverages its expertise in running markets by providing technology and managed services to third parties. In addition to its main regulated market, Euronext also operates Euronext GrowthTM and Euronext AccessTM, simplifying access to listing for SMEs. For the latest news, find us on Twitter (www.twitter.com/euronext) and LinkedIn (www.linkedin.com/company/euronext).


Disclaimer

This press release is for information purposes only and is not a recommendation to engage in investment activities. This press release is provided “as is” without representation or warranty of any kind. While all reasonable care has been taken to ensure the accuracy of the content, Euronext does not guarantee its accuracy or completeness. Euronext will not be held liable for any loss or damages of any nature ensuing from using, trusting or acting on information provided. No information set out or referred to in this publication may be regarded as creating any right or obligation. The creation of rights and obligations in respect of financial products that are traded on the exchanges operated by Euronext’s subsidiaries shall depend solely on the applicable rules of the market operator. All proprietary rights and interest in or connected with this publication shall vest in Euronext.

This press release speaks only as of this date. Euronext refers to Euronext N.V. and its affiliates. Information regarding trademarks and intellectual property rights of Euronext is located at www.euronext.com/terms-use.

   
Record changed: 2018-06-07

Advertisement

Picture Fairtec GmbH Worldwide Event Solutions 600x60px

More documents for Euronext (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Advertisement

Picture Berlin Partner HealthCapital Bionnale 2018 Germany June 600x60px




» top